Experiment 44700
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Camptotheca acuminata (NYSSACEAE) |
| Citation | MOERTEL,CG: SCHUTT,AJ: REITEMEIER,RJ: HAHN,RG:. (1972). PHASE II STUDY OF CAMPTOTHECIN (NSC-100880) IN THE TREATMENT OF ADVANCED GASTROINTESTINAL CANCER.. 56() |
| Amount utilized | |
| Compound isolated | |
| Disease | PHASE II CLINICAL TRIAL INVOLVING 61 PATIENTS WITH ADVANCED GASTROINTESTINAL ADENOCARCINOMA DOSE RANGED FROM 90-180 MG/SQ M ONCE EVERY 3 WEEKS(34 PATIENTS) 27 PATIENTS WERE GIVEN 5-DAY COURSES REPEATED EVERY 4 WEEKS AT INITIAL TOTAL DOSES OF 55-110 MG/SQ M TOXIC EFFECTS INCLUDED NAUSEA,VOMITING,DIARRHEA,STOMATITIS,DERMATITIS,ALOPECIA,HEMORRHAGIC CYSTITIS,LEUKOPENIA,THROMBOCYTOPENIA AND ANEMIA ONLY TWO PATIENTS(30%)SHOWED PARTIAL OBJECTIVE RESPONSES AFTER TWO MONTHS CONCLUSION OF AUTHORS: CAMPTOTHECIN IS A DRUG OF PROTEAN AND UNPREDICTABLE TOXICITY THAT HAS NO CLINICAL VALUE IN THE MANAGEMENT OF GASTROINTESTINAL CANCER. |
| Dose amount | 180.0 MG |
| Number | 1 |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |